Compounds by research area.

10 mg

Synthetic pentadecapeptide (15 aa), sequence derived from a gastric juice protein fragment.

BPC-157 is among the most extensively studied peptides in rodent models of connective-tissue injury. In transected rat Achilles tendon, systemic and local administration accelerated tendon-to-bone healing and improved biomechanical strength; in vitro, it stimulated tendocyte outgrowth, survival and migration. Proposed mechanisms include upregulation of growth-factor receptor signaling (EGR-1, VEGFR2), modulation of the nitric-oxide system, and effects on angiogenesis. The literature is predominantly rat and mouse; controlled veterinary trials in companion animals have not been published.

Topical spray

Topical formulation of BPC-157

Research summary in preparation.

10 mg

Tripeptide (Lys-Pro-Val), the C-terminal fragment of α-melanocyte-stimulating hormone (α-MSH 11–13).

KPV retains the anti-inflammatory activity of α-MSH without its melanotropic effects. In murine DSS- and TNBS-induced colitis, oral and systemic KPV reduced inflammatory cytokine expression, NF-κB activation and histologic injury, with uptake into intestinal epithelial cells reported via the PepT1 transporter. Additional in vitro work shows inhibition of TNF-α-stimulated NF-κB activity. Data are mouse and cell-based; there are no published veterinary trials.

Topical spray

Topical formulation of KPV

Research summary in preparation.

10 mg

Synthetic pentadecapeptide (15 aa), sequence derived from a gastric juice protein fragment.

BPC-157 is among the most extensively studied peptides in rodent models of connective-tissue injury. In transected rat Achilles tendon, systemic and local administration accelerated tendon-to-bone healing and improved biomechanical strength; in vitro, it stimulated tendocyte outgrowth, survival and migration. Proposed mechanisms include upregulation of growth-factor receptor signaling (EGR-1, VEGFR2), modulation of the nitric-oxide system, and effects on angiogenesis. The literature is predominantly rat and mouse; controlled veterinary trials in companion animals have not been published.

10 mg

Synthetic fragment of thymosin β4 (Tβ4), a 43-aa actin-sequestering protein.

Tβ4 regulates actin polymerization and is involved in cell migration, angiogenesis and reduction of inflammatory cytokines in preclinical wound and cardiac models. TB-500 reproduces the active actin-binding region (LKKTETQ) of Tβ4. Rodent studies report accelerated dermal wound closure and improved cell migration; equine interest stems from its historical use in racing contexts, which is also why it is prohibited in regulated competition. No controlled clinical trials in horses or dogs have been published.

BPC-157 10 mg + TB-500 10 mg

Fixed-ratio blend of two synthetic peptides in a single lyophilized vial.

Combines the two compounds most frequently paired in musculoskeletal-recovery research. BPC-157 acts primarily through growth-factor and NO-pathway signaling; Tβ4 fragments act through actin regulation and cell migration. The pairing is supported by mechanistic rationale rather than controlled combination studies. Supplied as a co-lyophilized blend to reduce reconstitution steps for research protocols.

10 mg

11-aa synthetic peptide derived from helix B of erythropoietin (EPO).

ARA-290 was engineered to engage the innate repair receptor (EPOR–βcR heterodimer) without erythropoietic activity, separating EPO's tissue-protective signaling from its effect on red-cell mass. Rodent studies report reduced neuropathic pain behaviors, improved small-fiber density and anti-inflammatory effects in models of diabetic neuropathy, sarcoidosis-like inflammation and ischemia. Human phase 2 data exist for sarcoidosis-associated small-fiber neuropathy; there is no published veterinary literature.

GHK-Cu 27 mg + BPC-157 5 mg + TB-500 10 mg

Fixed-ratio three-peptide blend (copper tripeptide, pentadecapeptide, Tβ4 fragment), single lyophilized vial.

GLOW pairs the collagen- and remodeling-related literature on GHK-Cu with the two peptides most studied in connective-tissue and dermal wound models. GHK-Cu has decades of data on collagen and glycosaminoglycan synthesis, fibroblast recruitment and metalloproteinase modulation, including canine wound-healing studies; BPC-157 and Tβ4 fragments contribute cell-migration, angiogenesis and growth-factor signaling data from rodent models. The three are supplied co-lyophilized for research protocols that call for co-administration. No controlled studies of this combination have been published; the rationale is mechanistic. The copper complex gives the reconstituted solution a characteristic blue tint.

BPC-157 10 mg + TB-500 10 mg + KPV 10 mg + GHK-Cu 50 mg

Fixed-ratio four-peptide blend, single lyophilized vial.

KLOW extends the GLOW combination with KPV, the α-MSH-derived tripeptide studied for anti-inflammatory activity in murine colitis and in vitro NF-κB models, and carries a higher GHK-Cu content. The blend brings together four bodies of preclinical literature: tissue repair and cell migration (BPC-157, Tβ4 fragment), collagen synthesis and dermal remodeling (GHK-Cu), and inflammatory signaling (KPV). Supplied co-lyophilized for research protocols that call for co-administration. No controlled studies of the four-way combination exist; the rationale is mechanistic. Blue tint on reconstitution is expected from the copper complex.

100 mg

Copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, a naturally occurring plasma peptide.

GHK-Cu is one of the best-characterized regenerative peptides, with decades of literature on collagen and glycosaminoglycan synthesis, fibroblast recruitment, antioxidant enzyme induction and modulation of metalloproteinase activity. Wound-healing studies span rat, rabbit, mouse and dog models, including improved closure of ischemic wounds and pad injuries in dogs. Gene-expression analysis suggests broad effects on tissue-remodeling and inflammatory pathways. Supplied as a lyophilized copper complex; the deep-blue color on reconstitution is characteristic.

Topical shampoo

Copper-peptide shampoo formulation

Research summary in preparation.

GHK-Cu 27 mg + BPC-157 5 mg + TB-500 10 mg

Fixed-ratio three-peptide blend (copper tripeptide, pentadecapeptide, Tβ4 fragment), single lyophilized vial.

GLOW pairs the collagen- and remodeling-related literature on GHK-Cu with the two peptides most studied in connective-tissue and dermal wound models. GHK-Cu has decades of data on collagen and glycosaminoglycan synthesis, fibroblast recruitment and metalloproteinase modulation, including canine wound-healing studies; BPC-157 and Tβ4 fragments contribute cell-migration, angiogenesis and growth-factor signaling data from rodent models. The three are supplied co-lyophilized for research protocols that call for co-administration. No controlled studies of this combination have been published; the rationale is mechanistic. The copper complex gives the reconstituted solution a characteristic blue tint.

BPC-157 10 mg + TB-500 10 mg + KPV 10 mg + GHK-Cu 50 mg

Fixed-ratio four-peptide blend, single lyophilized vial.

KLOW extends the GLOW combination with KPV, the α-MSH-derived tripeptide studied for anti-inflammatory activity in murine colitis and in vitro NF-κB models, and carries a higher GHK-Cu content. The blend brings together four bodies of preclinical literature: tissue repair and cell migration (BPC-157, Tβ4 fragment), collagen synthesis and dermal remodeling (GHK-Cu), and inflammatory signaling (KPV). Supplied co-lyophilized for research protocols that call for co-administration. No controlled studies of the four-way combination exist; the rationale is mechanistic. Blue tint on reconstitution is expected from the copper complex.

10 mg

Synthetic pentadecapeptide (15 aa), sequence derived from a gastric juice protein fragment.

BPC-157 is among the most extensively studied peptides in rodent models of connective-tissue injury. In transected rat Achilles tendon, systemic and local administration accelerated tendon-to-bone healing and improved biomechanical strength; in vitro, it stimulated tendocyte outgrowth, survival and migration. Proposed mechanisms include upregulation of growth-factor receptor signaling (EGR-1, VEGFR2), modulation of the nitric-oxide system, and effects on angiogenesis. The literature is predominantly rat and mouse; controlled veterinary trials in companion animals have not been published.

10 mg

Synthetic fragment of thymosin β4 (Tβ4), a 43-aa actin-sequestering protein.

Tβ4 regulates actin polymerization and is involved in cell migration, angiogenesis and reduction of inflammatory cytokines in preclinical wound and cardiac models. TB-500 reproduces the active actin-binding region (LKKTETQ) of Tβ4. Rodent studies report accelerated dermal wound closure and improved cell migration; equine interest stems from its historical use in racing contexts, which is also why it is prohibited in regulated competition. No controlled clinical trials in horses or dogs have been published.

BPC-157 10 mg + TB-500 10 mg

Fixed-ratio blend of two synthetic peptides in a single lyophilized vial.

Combines the two compounds most frequently paired in musculoskeletal-recovery research. BPC-157 acts primarily through growth-factor and NO-pathway signaling; Tβ4 fragments act through actin regulation and cell migration. The pairing is supported by mechanistic rationale rather than controlled combination studies. Supplied as a co-lyophilized blend to reduce reconstitution steps for research protocols.

GHK-Cu 27 mg + BPC-157 5 mg + TB-500 10 mg

Fixed-ratio three-peptide blend (copper tripeptide, pentadecapeptide, Tβ4 fragment), single lyophilized vial.

GLOW pairs the collagen- and remodeling-related literature on GHK-Cu with the two peptides most studied in connective-tissue and dermal wound models. GHK-Cu has decades of data on collagen and glycosaminoglycan synthesis, fibroblast recruitment and metalloproteinase modulation, including canine wound-healing studies; BPC-157 and Tβ4 fragments contribute cell-migration, angiogenesis and growth-factor signaling data from rodent models. The three are supplied co-lyophilized for research protocols that call for co-administration. No controlled studies of this combination have been published; the rationale is mechanistic. The copper complex gives the reconstituted solution a characteristic blue tint.

BPC-157 10 mg + TB-500 10 mg + KPV 10 mg + GHK-Cu 50 mg

Fixed-ratio four-peptide blend, single lyophilized vial.

KLOW extends the GLOW combination with KPV, the α-MSH-derived tripeptide studied for anti-inflammatory activity in murine colitis and in vitro NF-κB models, and carries a higher GHK-Cu content. The blend brings together four bodies of preclinical literature: tissue repair and cell migration (BPC-157, Tβ4 fragment), collagen synthesis and dermal remodeling (GHK-Cu), and inflammatory signaling (KPV). Supplied co-lyophilized for research protocols that call for co-administration. No controlled studies of the four-way combination exist; the rationale is mechanistic. Blue tint on reconstitution is expected from the copper complex.